266 related articles for article (PubMed ID: 36125701)
21. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J
Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386
[TBL] [Abstract][Full Text] [Related]
22. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Yamaoka K; Tanaka Y; Kameda H; Khan N; Sasaki N; Harigai M; Song Y; Zhang Y; Takeuchi T
Drug Saf; 2021 Jun; 44(6):711-722. PubMed ID: 34041702
[TBL] [Abstract][Full Text] [Related]
23. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories.
Pincus T; Swearingen CJ; Bergman M; Yazici Y
J Rheumatol; 2008 Nov; 35(11):2136-47. PubMed ID: 18793006
[TBL] [Abstract][Full Text] [Related]
24. A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis.
Harrold LR; Zueger P; Nowell WB; Blachley T; Schrader A; Lakin PR; Curtis D; Stradford L; Venkatachalam S; Tundia N; Patel PA
Rheumatol Ther; 2023 Dec; 10(6):1519-1533. PubMed ID: 37728861
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of five approved Janus kinase inhibitors as monotherapy and combination therapy in patients with moderate-to-severe active rheumatoid arthritis: a systematic review and network meta-analysis of randomized controlled trials.
Cai W; Tong R; Sun Y; Yao Y; Zhang J
Front Pharmacol; 2024; 15():1387585. PubMed ID: 38725657
[TBL] [Abstract][Full Text] [Related]
26. Performance of routine assessment of patient index data 3 (RAPID3) in monitoring disease activity of Chinese rheumatoid arthritis patients.
Zhang X; Xie A; Wang Y; Deng X; Geng Y; Ji L; Hao Y; Li G; Zhang Z
Int J Rheum Dis; 2018 Nov; 21(11):1940-1945. PubMed ID: 30402934
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Disease Activity Score in 28 joints with ESR (DAS28), Clinical Disease Activity Index (CDAI), Health Assessment Questionnaire Disability Index (HAQ-DI) & Routine Assessment of Patient Index Data with 3 measures (RAPID3) for assessing disease activity in patients with rheumatoid arthritis at initial presentation.
Kumar BS; Suneetha P; Mohan A; Kumar DP; Sarma KVS
Indian J Med Res; 2017 Nov; 146(Supplement):S57-S62. PubMed ID: 29578196
[TBL] [Abstract][Full Text] [Related]
28. A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
Edwards CJ; Sawant R; Garg V; Du EX; Friedman A; Betts KA
Rheumatol Ther; 2021 Mar; 8(1):167-181. PubMed ID: 33244703
[TBL] [Abstract][Full Text] [Related]
29. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
30. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort.
Castrejón I; Dougados M; Combe B; Guillemin F; Fautrel B; Pincus T
J Rheumatol; 2013 Apr; 40(4):386-93. PubMed ID: 23378463
[TBL] [Abstract][Full Text] [Related]
31. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
[TBL] [Abstract][Full Text] [Related]
32. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R
Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829
[TBL] [Abstract][Full Text] [Related]
33. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.
Conaghan PG; Mysler E; Tanaka Y; Da Silva-Tillmann B; Shaw T; Liu J; Ferguson R; Enejosa JV; Cohen S; Nash P; Rigby W; Burmester G
Drug Saf; 2021 May; 44(5):515-530. PubMed ID: 33527177
[TBL] [Abstract][Full Text] [Related]
34. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
35. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
Keystone EC; Ahmad HA; Yazici Y; Bergman MJ
Rheumatology (Oxford); 2020 Aug; 59(8):2090-2098. PubMed ID: 31819995
[TBL] [Abstract][Full Text] [Related]
36. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.
Khawaja MN; Bergman MJ; Yourish J; Pei J; Reiss W; Keystone E
Arthritis Care Res (Hoboken); 2017 May; 69(5):609-615. PubMed ID: 27564431
[TBL] [Abstract][Full Text] [Related]
37. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
Mease P; Kavanaugh A; Gladman D; FitzGerald O; Soriano ER; Nash P; Feng D; Lertratanakul A; Douglas K; Lippe R; Gossec L
Rheumatol Ther; 2022 Aug; 9(4):1181-1191. PubMed ID: 35606663
[TBL] [Abstract][Full Text] [Related]
38. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
[TBL] [Abstract][Full Text] [Related]
39. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study.
Lee SW; Kim SY; Chang SH
BMC Musculoskelet Disord; 2019 Sep; 20(1):420. PubMed ID: 31506089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
